The Joint Committee on Vaccination and Immunisation (JCVI) published interim advice on a potential COVID-19 booster vaccination programme on 30 June, which is available at the following link:<\/p>
https://www.gov.uk/government/publications/jcvi-interim-advice-on-a-potential-coronavirus-covid-19-booster-vaccine-programme-for-winter-2021-to-2022<\/a><\/p> The JCVI recommends a two staged approach is recommended, with those in the first stage offered a booster and flu vaccine as soon as possible from September. Those in the second stage would be offered a booster vaccine as soon as practicable after stage one, with equal emphasis on deployment of the flu vaccine where eligible.<\/p> Final decisions on the timing and scope of the vaccine booster\u202fprogramme, as well as cohorts and eligibility,\u202fwill be made later in the year, informed by further independent advice from the JCVI. This includes further data on the durability of protection from vaccines, data supplied by manufacturers and clinical trial data regarding COVID-19 vaccine and flu vaccine coadministration. On 1 July, NHS England and NHS Improvement wrote to primary care providers, including community pharmacies, outlining the JCVI\u2019s interim advice to allow local planning to begin.<\/p> <\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4113", "label" : {"_value" : "Biography information for Nadhim Zahawi"}
}
, "answeringMemberConstituency" : {"_value" : "Stratford-on-Avon"}
, "answeringMemberPrinted" : {"_value" : "Nadhim Zahawi"}
, "dateOfAnswer" : {"_value" : "2021-07-13", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2021-07-13T16:05:46.03Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2021-07-05", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Coronavirus and Influenza: Vaccination"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, whether covid-19 booster vaccines and flu vaccines will be delivered (a) at the same time and (b) in pharmacies.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4131", "label" : {"_value" : "Biography information for Jim Shannon"}
}
, "tablingMemberConstituency" : {"_value" : "Strangford"}
, "tablingMemberPrinted" : [{"_value" : "Jim Shannon"}
], "uin" : "27158"}
, {"_about" : "http://data.parliament.uk/resources/1331201", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1331201/answer", "answerText" : {"_value" : " Deployment decisions for the Janssen vaccine within the COVID-19 vaccine programme are currently under consideration. The Department will be guided by the advice from the Joint Committee on Vaccination and Immunisation before making a final decision.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4113", "label" : {"_value" : "Biography information for Nadhim Zahawi"}
}
, "answeringMemberConstituency" : {"_value" : "Stratford-on-Avon"}
, "answeringMemberPrinted" : {"_value" : "Nadhim Zahawi"}
, "dateOfAnswer" : {"_value" : "2021-06-18", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2021-06-18T12:21:05.58Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2021-06-09", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Coronavirus: Vaccination"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, whether his Department has made an assessment of who should be eligible to receive the Janssen covid-19 vaccine.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4131", "label" : {"_value" : "Biography information for Jim Shannon"}
}
, "tablingMemberConstituency" : {"_value" : "Strangford"}
, "tablingMemberPrinted" : [{"_value" : "Jim Shannon"}
], "uin" : "13066"}
, {"_about" : "http://data.parliament.uk/resources/1327693", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1327693/answer", "answerText" : {"_value" : " The delivery of the vaccination programme is designed to be convenient and flexible, including in areas where there are groups with lower uptake. There is already a wide offer of vaccination settings such as religious and community centres. Local and national public health agencies are consulted on how best to utilise this flexibility to maximise uptake in groups with low vaccine uptake.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4113", "label" : {"_value" : "Biography information for Nadhim Zahawi"}
}
, "answeringMemberConstituency" : {"_value" : "Stratford-on-Avon"}
, "answeringMemberPrinted" : {"_value" : "Nadhim Zahawi"}
, "dateOfAnswer" : {"_value" : "2021-06-03", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2021-06-03T16:41:08.83Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2021-05-25", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Coronavirus: Vaccination"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, if he will make an assessment of the potential merits of using community development centres to help promote and administer the covid19 vaccine in areas where the take-up of the vaccine is lower than average.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4131", "label" : {"_value" : "Biography information for Jim Shannon"}
}
, "tablingMemberConstituency" : {"_value" : "Strangford"}
, "tablingMemberPrinted" : [{"_value" : "Jim Shannon"}
], "uin" : "7178"}
, {"_about" : "http://data.parliament.uk/resources/1314407", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1314407/answer", "answerText" : {"_value" : " Public Health England publishes weekly COVID-19 vaccine surveillance reports which include the latest evidence on vaccine effectiveness against different outcomes, which is estimated by comparing rates of disease in vaccinated individuals to rates in unvaccinated individuals. The reports provide a summary of evidence on vaccine effectiveness against different outcomes for Pfizer/BioNTech and Oxford/AstraZeneca, including symptomatic disease, hospitalisation, mortality, infection and transmission. The latest report is available at the following link:<\/p> https://www.gov.uk/government/publications/covid-19-vaccine-surveillance-report<\/a><\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4113", "label" : {"_value" : "Biography information for Nadhim Zahawi"}
}
, "answeringMemberConstituency" : {"_value" : "Stratford-on-Avon"}
, "answeringMemberPrinted" : {"_value" : "Nadhim Zahawi"}
, "dateOfAnswer" : {"_value" : "2021-05-21", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2021-05-21T12:17:54.313Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2021-05-13", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Coronavirus: Vaccination"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, what recent estimate he has made of the level of protection given by each of the covid-19 vaccines available.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4131", "label" : {"_value" : "Biography information for Jim Shannon"}
}
, "tablingMemberConstituency" : {"_value" : "Strangford"}
, "tablingMemberPrinted" : [{"_value" : "Jim Shannon"}
], "uin" : "1061"}
, {"_about" : "http://data.parliament.uk/resources/1308454", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1308454/answer", "answerText" : {"_value" : " All currently deployed COVID-19 vaccines in the United Kingdom are effective against the prevalent strains in the country.<\/p> Public Health England has published early estimates of vaccine effectiveness which includes the United Kingdom variant of concern VOC202012/01 and has shown no substantial change in vaccine effectiveness against this variant, which is now the dominant strain of COVID-19 in the UK. If other emerging variants do reduce vaccine efficacy, it would still be anticipated that the vaccines currently in deployment would continue to provide protection to some extent.<\/p> The Government are already taking several steps to understand the efficacy of the current UK vaccine portfolio against new and emerging virus variants. This includes a partnership with CureVac to develop a variation of an existing vaccine tailored to the most appropriate variant target.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4113", "label" : {"_value" : "Biography information for Nadhim Zahawi"}
}
, "answeringMemberConstituency" : {"_value" : "Stratford-on-Avon"}
, "answeringMemberPrinted" : {"_value" : "Nadhim Zahawi"}
, "dateOfAnswer" : {"_value" : "2021-04-20", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2021-04-20T15:31:12.037Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2021-04-13", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Coronavirus: Vaccination"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, whether certain variants of covid-19 are less susceptible to vaccines.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4131", "label" : {"_value" : "Biography information for Jim Shannon"}
}
, "tablingMemberConstituency" : {"_value" : "Strangford"}
, "tablingMemberPrinted" : [{"_value" : "Jim Shannon"}
], "uin" : "180499"}
, {"_about" : "http://data.parliament.uk/resources/1306217", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1306217/answer", "answerText" : {"_value" : " If elite level athletes are captured in phase one or two of the programme due to age or clinical need, then they will be vaccinated accordingly. However, we are not currently planning to prioritise elite level athletes for COVID-19 vaccination.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4113", "label" : {"_value" : "Biography information for Nadhim Zahawi"}
}
, "answeringMemberConstituency" : {"_value" : "Stratford-on-Avon"}
, "answeringMemberPrinted" : {"_value" : "Nadhim Zahawi"}
, "dateOfAnswer" : {"_value" : "2021-04-13", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2021-04-13T09:03:14.223Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2021-03-25", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Coronavirus: Vaccination"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, whether he has plans to prioritise elite level athletes for early covid-19 vaccinations in light of the progress of the vaccination programme.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4131", "label" : {"_value" : "Biography information for Jim Shannon"}
}
, "tablingMemberConstituency" : {"_value" : "Strangford"}
, "tablingMemberPrinted" : [{"_value" : "Jim Shannon"}
], "uin" : "175850"}
, {"_about" : "http://data.parliament.uk/resources/1304063", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1304063/answer", "answerText" : {"_value" : " At present, there is very limited data on vaccination in adolescents with no data on vaccination in younger children. The Joint Commission on Vaccination and Immunisation advises that only those children at very high risk of exposure and serious outcomes, such as older children with severe neuro-disabilities that require residential care, should be offered vaccination as part of phase one. The Green Book also sets out that children under 16 years of age, even if they are clinically extremely vulnerable, are at low risk of serious morbidity and mortality and given the absence of safety and efficacy data on the vaccine, are not recommended for vaccination. Vaccine trials including on those under 18 years old are the responsibility of vaccine developers. We are aware of a number of planned COVID-19 vaccine trials in children and will monitor the results closely.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4113", "label" : {"_value" : "Biography information for Nadhim Zahawi"}
}
, "answeringMemberConstituency" : {"_value" : "Stratford-on-Avon"}
, "answeringMemberPrinted" : {"_value" : "Nadhim Zahawi"}
, "dateOfAnswer" : {"_value" : "2021-03-25", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2021-03-25T15:17:19.343Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2021-03-18", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Coronavirus: Screening and Vaccination"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential merits of vaccinating secondary pupils against covid-19; and whether tests on children aged over 11 have been undertaken on the safety of the covid-19 vaccine for that age group.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4131", "label" : {"_value" : "Biography information for Jim Shannon"}
}
, "tablingMemberConstituency" : {"_value" : "Strangford"}
, "tablingMemberPrinted" : [{"_value" : "Jim Shannon"}
], "uin" : "171605"}
, {"_about" : "http://data.parliament.uk/resources/1303281", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1303281/answer", "answerText" : {"_value" : " To assist general practitioners (GPs) identify patients eligible for a vaccine in each priority cohort, NHS Digital has aligned specifications for the identification of patients via their medical records with GP system suppliers. Asthma sufferers will be identified through this system and invited to make an appointment when the vaccination programme has reached their respective priority cohort.<\/p> <\/p> To date, chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) has not been identified as either a condition that makes an individual clinically extremely vulnerable or as a condition that would place an individual at increased clinical risk from COVID-19. GPs will therefore not specifically be identifying CFS/ME patients for COVID-19 vaccines via their medical records. It is more likely that patients with CFS/ME will be offered COVID-19 vaccines because they are eligible through other means such as their age, or they have other underlying health issues that would put them at increased clinical risk.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4113", "label" : {"_value" : "Biography information for Nadhim Zahawi"}
}
, "answeringMemberConstituency" : {"_value" : "Stratford-on-Avon"}
, "answeringMemberPrinted" : {"_value" : "Nadhim Zahawi"}
, "dateOfAnswer" : {"_value" : "2021-04-08", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2021-04-08T09:02:10.01Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2021-03-17", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Coronavirus: Vaccination"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, what steps he is taking to ensure that GPs are able to identify (a) asthma and (b) ME patients for the covid-19 vaccine through their medical records.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4131", "label" : {"_value" : "Biography information for Jim Shannon"}
}
, "tablingMemberConstituency" : {"_value" : "Strangford"}
, "tablingMemberPrinted" : [{"_value" : "Jim Shannon"}
], "uin" : "170640"}
, {"_about" : "http://data.parliament.uk/resources/1293264", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1293264/answer", "answerText" : {"_value" : " Public Health England has published early estimates of vaccine effectiveness which includes the United Kingdom variant of concern VOC202012/01, which is available at the following link:<\/p> <\/p>